• Revolution Medicines’ Rasonque received a positive CHMP opinion recommending EU authorization for adults with metastatic pancreatic adenocarcinoma following prior systemic therapy.
• European Commission approval remains pending; the drug reduced death risk by 60% versus chemotherapy in the Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150945PRIMZONEFULLFEED9846575) on October 15, 2026, and is solely responsible for the information contained therein.